These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 3509332)
1. Per-oral controlled release dosage form of theophylline using soybean protein. Machida Y; Tokumura T; Nagai T Drug Des Deliv; 1987 Feb; 1(3):187-92. PubMed ID: 3509332 [TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo sustained-release characteristics of theophylline matrix tablets and novel cluster tablets. Hayashi T; Kanbe H; Okada M; Kawase I; Ikeda Y; Onuki Y; Kaneko T; Sonobe T Int J Pharm; 2007 Aug; 341(1-2):105-13. PubMed ID: 17512147 [TBL] [Abstract][Full Text] [Related]
3. Design and evaluation of a controlled-release theophylline tablet. Preliminary communication. Gai MN; Pezoa R; Corbeaux J; Arancibia A Farmaco; 1989 Nov; 44(11):1119-26. PubMed ID: 2701966 [TBL] [Abstract][Full Text] [Related]
4. In-vitro and in-vivo evaluation of enteric-coated starch-based pellets prepared via extrusion/spheronisation. Dukić-Ott A; De Beer T; Remon JP; Baeyens W; Foreman P; Vervaet C Eur J Pharm Biopharm; 2008 Sep; 70(1):302-12. PubMed ID: 18579353 [TBL] [Abstract][Full Text] [Related]
5. Use of soybean protein for controlled release of drugs administered orally. Machida Y; Tokumura T; Nagai T Drug Des Deliv; 1987 Feb; 1(3):179-86. PubMed ID: 3509331 [TBL] [Abstract][Full Text] [Related]
6. A study on maize proteins as a potential new tablet excipient. Georget DM; Barker SA; Belton PS Eur J Pharm Biopharm; 2008 Jun; 69(2):718-26. PubMed ID: 18294824 [TBL] [Abstract][Full Text] [Related]
7. High-amylose carboxymethyl starch matrices for oral sustained drug-release: in vitro and in vivo evaluation. Nabais T; Brouillet F; Kyriacos S; Mroueh M; Amores da Silva P; Bataille B; Chebli C; Cartilier L Eur J Pharm Biopharm; 2007 Mar; 65(3):371-8. PubMed ID: 17275270 [TBL] [Abstract][Full Text] [Related]
8. In vivo evaluation of a theophylline oral controlled-release unit dosage form. Gangadharan B; Ritschel WA; Hussain SA Arzneimittelforschung; 1987 Nov; 37(11):1256-7. PubMed ID: 3440033 [TBL] [Abstract][Full Text] [Related]
9. In vitro/in vivo evaluation of hydrochlorothiazide in experimental hydrochlorothiazide/triamterene combination tablets in beagle dogs. Ritschel WA; Turkoglu M; Lipps D; Warner A; Sakr A Arzneimittelforschung; 1991 Mar; 41(3):208-11. PubMed ID: 1867656 [TBL] [Abstract][Full Text] [Related]
10. Development of novel sustained-release system, disintegration-controlled matrix tablet (DCMT) with solid dispersion granules of nilvadipine (II): in vivo evaluation. Tanaka N; Imai K; Okimoto K; Ueda S; Tokunaga Y; Ibuki R; Higaki K; Kimura T J Control Release; 2006 May; 112(1):51-6. PubMed ID: 16545477 [TBL] [Abstract][Full Text] [Related]
11. Comparison of gastroretentive microspheres and sustained-release preparations using theophylline pharmacokinetics. Miyazaki Y; Yakou S; Takayama K J Pharm Pharmacol; 2008 Jun; 60(6):693-8. PubMed ID: 18498704 [TBL] [Abstract][Full Text] [Related]
12. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers. Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557 [TBL] [Abstract][Full Text] [Related]
13. In vivo evaluation of two new sustained release formulations elaborated by one-step melt granulation: level A in vitro-in vivo correlation. Ochoa L; Igartua M; Hernández RM; Solinís MA; Gascón AR; Pedraz JL Eur J Pharm Biopharm; 2010 Jun; 75(2):232-7. PubMed ID: 20159037 [TBL] [Abstract][Full Text] [Related]
14. Theophylline controlled-release formulations: in vivo-in vitro correlations. Yu Z; Schwartz JB; Sugita ET Biopharm Drug Dispos; 1996 Apr; 17(3):259-72. PubMed ID: 8983400 [TBL] [Abstract][Full Text] [Related]
15. Comparative bioavailability and in vitro in vivo correlation of two sustained release brands of theophylline: tablets and pellets. Tulain U; Ur-Rahman N Pak J Pharm Sci; 2008 Apr; 21(2):131-8. PubMed ID: 18390443 [TBL] [Abstract][Full Text] [Related]
16. [Release, absorption and elimination of theophylline from fast and slowly released oral formulations]. Frömming KH; Schwabe L; Staib AH; Rietbrock N; Lassmann A; Molz KH; Schuppan D; Siebert-Weigel M; Voegele D Arzneimittelforschung; 1983; 33(3):446-52. PubMed ID: 6683521 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of the effect of 3 different diets on the bioavailability of 2 sustained release theophylline matrix tablets. Gai MN; Isla A; Andonaegui MT; Thielemann AM; Seitz C Int J Clin Pharmacol Ther; 1997 Dec; 35(12):565-71. PubMed ID: 9455715 [TBL] [Abstract][Full Text] [Related]
18. Invivo absorption behaviour of theophylline from starch-methyl methacrylate matrix tablets in beagle dogs. Fernández-Campos F; Ferrero C; Colom H; Jiménez-Castellanos MR Int J Pharm; 2015 Jan; 478(2):684-92. PubMed ID: 25476254 [TBL] [Abstract][Full Text] [Related]
19. Absorption of theophylline from conventional and sustained-release tablets. Fagerström PO; Mellstrand T; Svedmyr N Int J Clin Pharmacol Ther Toxicol; 1981 Mar; 19(3):131-8. PubMed ID: 7228455 [TBL] [Abstract][Full Text] [Related]
20. [Sustained-release effect of the direct compressed tablet based on chitosan and Na alginate]. Yomota C; Miyazaki T; Okada S Yakugaku Zasshi; 1994 Apr; 114(4):257-63. PubMed ID: 8201547 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]